Loud Opposition To March-In Petition Might Signal Close Call

By Gabrielle Wanneh / March 21, 2022 at 6:38 PM
About 80 drug industry groups and individuals are urging the National Institutes of Health to reject a petition for the government to march in on Xtandi patents to make a cheaper generic to the prostate cancer drug with an annual list price of about $190,000. The March 17 letter is a sign that the industry is worried the Biden administration is considering the march-in petition more seriously than past administrations have considered similar petitions. Four prostate cancer patients petitioned the...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.